• Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations
• A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform
• Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents
• By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million

The exploding interest in cannabis products and in new ways of enjoying them has proven fertile ground for drug technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) as it markets the company’s revolutionary DehydraTECH platform for increasing the absorption rates of varied edible substances, including nicotine and cannabidiol (CBD).

DehydraTECH is a drug delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced July 24, the company will expand DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V: BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine, and adult format beverages, to produce commercial products in partnership with Lexaria under a new brand that is yet to be announced (http://ibn.fm/BTodZ).

The new brand will include processed tetrahydrocannabinol (THC) and/or cannabidiol (CBD) powder ingredients from cannabis for the Canadian market. The agreement will be in force for 10 years. Both companies expect the arrangement to create the potential of enhanced cashflow, and Lexaria, in particular, is anticipated to benefit from the emerging federally legal cannabis edibles industry in Canada, where edible cannabis products will be allowed under new laws beginning in October.

The new joint manufacturing partnership will create a mechanism for intermediate ingredients made from DehydraTECH-processed cannabis and hemp powders to be sold for the first time on a business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The powders are stable, with a two-to-three-year shelf life, and are odorless and tasteless, providing a full-spectrum cannabis experience for nearly any ingestible product format.

“When we first began our relationship with Lexaria it was based on a comprehensive competitive review of the market with a single uncompromising vision: to find a technology partner who could provide water soluble cannabis, with zero impact on the award-winning taste and aroma of our products,” Terry Donnelly, chairman and CEO of Hill Street, stated in a news release. “This partnership takes our relationship to a whole new level, which we believe will help to set a global standard for excellence that consumers are looking for in cannabis edibles and beverages.”

In addition to the rapid onset of ingested cannabis’ effect enabled by DehydraTECH, the technology creates a mechanism for stronger peak delivery of the effect through higher peak blood concentrations, as demonstrated in third-party lab tests. The technology also delivers the benefit of a “fast-off” effect, with the initial peak followed four hours later by lower cannabinoid content in the blood than some competitors’ nanotech-enabled formulations, leading to a shorter-duration experience that many consumers prefer as they resume other activities.

Hill Street is the only company to gain semi-exclusive licenses to use the DehydraTECH CBD beverage infusion technology in global markets around the world. DehydraTECH has received 11 patents in the United States and Australia and has about 60 additional patents pending in more than 40 countries worldwide.

Food and drink consultancy Zenith Global predicts that the U.S. market for cannabis- and hemp-infused drinks will balloon by nearly 15 times last year’s revenues of $89 million to over $1.4 billion by 2024 (http://ibn.fm/PgbKH).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Prelaunch of the company’s cannabis delivery service, Viva Buds Inc., was recently announced, with signups now being accepted as the official August launch date nears
• MCOA’s revolutionary, nourishing cosmetic topical CBD formula, hempSMART Body Cream, is designed to set a new industry standard by helping to improve overall skin health
• The company’s expansion of wholly owned subsidiary hempSMART Ltd. into Europe continued with its recent entry into the Netherlands

Marijuana Company of America Inc. (OTCQB: MCOA), an innovative hemp and cannabis corporation, continues to expand its portfolio with new products and avenues of customer service. As pioneers in the cannabis industry, dating back to 2009 when MCOA CEO Don Steinberg founded the first marijuana company ever to trade on a U.S. stock market (Medical Marijuana Inc.), MCOA has stayed at the forefront of the cannabis and hemp industry.

The establishment of a joint venture with Natural Plant Extract of California (“NPE”), along with a 20 percent ownership stake in the company, led to the creation of Viva Buds Inc., a unique, Los Angeles, California-based cannabis delivery service. MCOA’s commitment to the joint venture is evident in a recent news release (http://ibn.fm/rLE91) announcing the acceptance of potential customers during a prelaunch of Viva Buds’ cannabis delivery service in the San Fernando Valley in the Los Angeles area.

Interested adult consumers can sign up now at www.VivaBuds.com, which will give customers several advantages before the official August 2019 launch date, including the ability to build their own personal cannabis business utilizing a “call your friend” approach (http://ibn.fm/mIiIY).

The joint venture calls for MCOA and NPE to share in the net profits on a 50-50 basis, with NPE managing all operations pertaining to distribution, manufacturing and delivery of cannabis products, while MCOA provides capital, consulting and marketing services. “It’s an innovative opportunity in one of the largest U.S. markets for recreational cannabis,” Steinberg said in a news release.

MCOA’s hempSMART brand is also launching a revolutionary, nourishing topical CBD-infused cosmetic product called hempSMART Body Cream (http://ibn.fm/VWB5S). Each bottle of hempSMART Body Cream is formulated with 300 mg of organically grown, full spectrum, non-psychoactive cannabidiol derived from industrial hemp.

“Combining premium CBD oil with a unique blend of synergistic Ayurvedic herbs and botanicals illustrates a major advancement in the wellness arena,” added Paula Vetter, a holistic nurse practitioner and certified herbalist who is also chair of the hempSMART medical advisory board. “The cream is completely free of toxins that are commonly found in many skin care products and absorbed through the skin and into the blood stream… Instead, hempSMART’s Body Cream is a topical wellness solution that sets a new standard in the industry by improving the overall health of skin with each use.”

The hempSMART product line distinguishes itself from competitors through its premier quality extracts derived from industrial hemp plants grown specifically to provide the highest concentration of CBD. In fact, hempSMART products received such positive feedback during a launch in the United Kingdom in March 2019 that MCOA was encouraged to expand its European footprint into the Netherlands through its wholly owned subsidiary, hempSMART Ltd., in June 2019 (http://ibn.fm/7p9YG).

“The Netherlands launch was a complete success, with people traveling from other parts of Europe to witness the excitement around our hempSMART CBD product line,” Ian Harvey, global sales director of hempSMART, noted. “The event featured our CEO, Don Steinberg, unveiling our wellness products via video link and educating people about the benefits of our prime quality botanical ingredients. Our products sold out at the end of the event, and we engaged new marketing associates for hempSMART as evangelists to the brand that will help spread our vision.”

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Blue Hat reported 52 percent revenue growth and 76 percent net income growth for the nine months ended September 30, 2018
• The company maintains a vast portfolio of proprietary technologies, patents, artwork copyrights, trademarks and software copyrights
• Retail sales of toys and games in China surged from RMB111.8 billion in 2012 to RMB276.6 billion in 2017
• Global trends and government policies favor further growth

The toy industry is not a frivolous pastime. In fact, the toy business offers a wealth of opportunity. The United States is currently the largest segment of global toy sales. However, in terms of growth prospects, the toy market in Asia is on a tear, growing by a whopping 20 percent from 2012 to 2017. China’s market for toys and video games, now worth $45 billion, is expected to bypass America in just a few years (http://ibn.fm/pQrXP). With this expansion, modern consumers are looking for unique products that go far beyond the typical and deliver a wow factor.

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) delivers that wow factor, creating the toys and games that parents want and children enjoy. Blue Hat is a leading innovator, producer and operator of augmented reality (AR) interactive entertainment games and smart toys in China. Retail sales of toys and games in China surged from RMB111.8 billion in 2012 to RMB276.6 billion in 2017, and Blue Hat is at the vanguard of this growth.

Blue Hat reported eye-popping 76 percent net income growth in the nine months ended September 30, 2018, serving as obvious evidence that the company’s toys, games and educational products are being embraced by the public. Such explosive growth far outpaces the growth of the industry and may be indicative of what’s to come.

Blue Hat’s popular product lines include mobile games, interactive educational materials and toys with built-in mobile game features. The company’s sophisticated mobile-connected entertainment platform enables the connection of physical items to mobile devices through wireless technologies, creating a vibrant interactive user experience.

Utilizing state-of-the-art technology, Blue Hat employs augmented reality (AR), motion capture technology, image recognition technology, voice control, light sensing technology, infrared, levitation induction and proprietary techniques to create toys and games that children love. The company also combines AR technology with education by integrating its products into situational teaching, roleplaying and man-machine interaction use cases.

With more products in development, Blue Hat currently has 161 authorized patents, 56 registered trademarks, 645 copyrights and 25 software copyrights. The company has developed sales channels and long-term relationships with preferred distributors. Its AR interactive entertainment products are sold in well-known international retail chains such as Toys ‘R’ Us, as well as other retail outlets. Blue Hat also has integrated online and offline sales channels with e-commerce giants like Alibaba, and it owns a busy brick and mortar store in Xiamen, China.

For more information, visit the company’s website at www.BlueHatGroup.net

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

• BMW is among the leaders in the automotive industry in its efforts to improve environmental sustainability through the use of natural, biodegradable products and electrical power systems that eliminate carbon emissions
• The company’s BMW i sub-brand utilizes natural hemp fibers in strong biocomposites for vehicle bodies that provide environmentally friendly appeal while maintaining physical integrity
• BMW’s i3 was the among the top-three best-selling all-electric vehicles for three years in a row, demonstrating the market demand for BMW’s vision of earth-friendly production

Pioneers crossing the North American Great Plains during the 19th Century used hemp canvas to outfit their covered wagons and protect them from the ravages of nature. In the 21st Century, automobile drivers crossing vast tracts of land at much greater speeds in vehicles manufactured by BMW Group (OTC: BMWYY) may be traveling in models that upgrade hemp’s utility in strong biocomposites to protect nature from the ravages of mankind.

BMW made waves with the introduction of its electric vehicle BMW i sub-brand in 2011 (http://ibn.fm/2KpMS) to showcase its vision for futuristic body designs using renewable and recycled materials, exemplified by the launch of its first “zero emissions” mass-produced vehicle, the i3, in 2013 and its companion i8 model (http://ibn.fm/jmOmt). The i3 was the first large-volume vehicle on the market to feature carbon-fiber reinforced plastic (“CFRP”), a very lightweight material incorporating hemp biocomposites to help make it more biodegradable while exhibiting two to three times the strength of steel (http://ibn.fm/uBTbF).

For three years in a row, through 2016, the i3 was ranked third by worldwide sales among all-electric cars (http://ibn.fm/B5dEf), demonstrating the market demand for BMW’s approach to automobiles with a smaller carbon footprint. The company boasts that 95 percent of the i3’s materials are recyclable.

Worldwide, the number of electric vehicles on the road grew by 54 percent in 2017 as concerns about global climate change, believed to be a result of human-caused pollution, led a multinational governmental policy response in the form of the Paris Agreement, which calls for the evolution of the petroleum-fueled auto industry (http://ibn.fm/Bi5XT).

California announced that it plans to have 5 million electric vehicles on its roads by 2025, and at least eight other U.S. states followed its lead in establishing an annual sales target of 15.4 percent electric vehicles as part of the total auto trade (http://ibn.fm/5iDiW). China is leading global sustainability efforts, with plans for 2 million EV sales by 2020. The nation reported that its sales of EVs already topped 1.1 million during 2018, marking more than 55 percent of all electric vehicles sold worldwide at a time when U.S. electric vehicle sales were at just 358,000 (http://ibn.fm/gY6lW).

Automakers’ use of natural fibers such as hemp are one example of efforts to improve ecological sustainability by increasing fuel economy, lightening vehicle weight, reducing use of nonbiodegradable plastics, and pairing vehicles with EV energy trains, thereby eliminating the carbon emissions that petroleum adds to the atmosphere.

For more information, visit the company’s website at www.BMWGroup.com

• INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan
• Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions
• The congress was a paramount event in the field of immunotherapy, allowing researchers to network, exchange ideas and discuss recent developments

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a major immunotherapy industry congress.

The 17th Annual Congress of International Drug Discovery Science & Technology, held on July 26 in Japan, brought together several immunotherapy industry leaders and provided excellent networking opportunities while facilitating the exchange of ideas and recent developments in the industry, as the company noted in a press release (http://ibn.fm/fzlta).

At the congress, INmune Bio co-founder and CEO R.J. Tesi, M.D, gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’, which highlighted monotherapy with checkpoint inhibitors (CPI) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, Tesi explained.

INmune Bio Director of Neuroscience C.J. Barnum also delivered a presentation on immunological disease and neurodegenerative disease, titled ‘Neurodegenerative Disease as an Immunological Disease: Role of Biomarkers’. The presentation focused on the link between neuroinflammation and Alzheimer’s disease, as well as the INmune phase I trial evaluating the treatment of patients with dementia through a precision medicine approach.

The company’s innovative drug candidate, XPro1595, targets neuroinflammation. It works by affecting microglial immune cells in the brain. Research suggests that these cells get activated in many patients with Alzheimer’s disease, contributing to neuroinflammation and promoting synaptic dysfunction.

A phase I clinical trial of XPro1595 involves 18 patients and is expected to continue throughout the summer of 2019. INmune Bio aims to measure both traditional and novel biomarkers in the patients to assess inflammation in those who have mild to moderate Alzheimer’s disease. The Alzheimer’s Association is providing financial support for the clinical trial in the form of a $1 million grant.

As the prominence of Alzheimer’s disease increases, seeking an adequate treatment option is becoming a more important task than ever before. Studies show that the prevalence of Alzheimer’s disease doubles every five years, and it already affects 40 percent of the population in the 90-94 age group (http://ibn.fm/2HX7N). The prevalence of Alzheimer’s disease is also anticipated to grow in the 65+ age group. In 2000, 6.8 percent of people in that age group were affected, but the figure will reach 16.2 percent by 2050.

INmune Bio is a publicly traded clinical-stage biotechnology company focusing on the development of therapies that target the immune system to fight or control disease. Currently, the company is working on three product platforms – two products that modify patients’ innate immune responses to cancer and one product, XPro1595, that targets neuroinflammation linked to Alzheimer’s disease. All of the INmune Bio product platforms utilize a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• The company’s new unit enables users to monitor battery life while controlling cloud, taste and activation
• The “must-have” device allows users to vape both nicotine pods and 510-thread prefilled cartridges
• VPRB’s CEO says that the company is focused on international sales growth and planting seeds for the future

VPR Brands LP (OTC: VPRB), a market leader in vaporizer technology in the cannabis space, is remaking the vaping experience with the premarket release of its newest innovative product, the HoneyStick Brand BeeBox Pro Device (http://ibn.fm/g7HA7).

The HoneyStick Brand BeeBox Pro Device aims to optimize its users’ experience by implementing several new features. The new unit features an LCD screen that enables users to monitor battery life. The new device also allows users to control vaping intensity levels by simply turning a dial, and it features push-button activation for the cart function and auto-draw activation for the pod function. With HoneyStick’s BeeBox Pro Device, users can control cloud, taste and activation.

“We thought of everything, like being able to run the pod portal on auto draw (inhalation activated), and the 510 cart is folded into the body and operates on push-button activation, making this a true dual-function vaporizer battery,” VPR Brands COO Dan Hoff stated in a news release.

“This is a must-have device for anyone who vapes both nicotine and cannabis — the best of both worlds,” added VPRB CEO Kevin Frija. “The BeeBox Pro is another one-of-a-kind, first-to-market product from HoneyStick.”

VPRB said that the device eliminates the need for users to carry two different pens. The BeeBox Pro allows users to vape nicotine pods and 510-thread prefilled cartridges from the same high-capacity power plant, solving the two-pen problem and offering the user a better vape experience.

In an interview with NetworkNewsAudio, Frija said, “All three of our verticals are very popular overseas as well. The overseas market accounts for probably more than the U.S. market on a combined basis with all the countries overseas. So we have been planting seeds in specific countries that have been friendly to Canada, CBD and the like, in order to build a foundation for the brand internationally.”

“We have our director of international sales, Ezequiel Pavlotsky, who is traveling Europe this year and has opened up key distributors in different countries,” Frija continued (http://ibn.fm/JpOuj). “We are just beginning to scratch the surface internationally, and we look forward to continuing to expand that effort. It has been very successful so far. It is taking time, but it is going to be fruitful when we’re finished.”

In addition to its pre-market release of the BeeBox Pro, VPR Brands recently reported solid financial gains, showing a 31 percent year-over-year sales gain to $1,318,049 for the three months ended March 31, 2019, up from $1,001,162 for the comparable period in 2018. The company cut its net loss in the 2019 period to $138,684 from $149,420 last year and maintained gross operating margins in excess of 40 percent (http://ibn.fm/Vbdu5).

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Retail sales of toys and games in China soared from RMB111.8 billion in 2012 to RMB276.6 billion in 2017, registering an average annual growth rate of nearly 20 percent
• Favorable Chinese government policies emphasize the research and development of new technologies such as augmented reality (AR) and virtual reality (VR)
• The global trend toward AR and VR products is expected to increase dramatically from 2018 to 2025, with market value projected to reach $767 billion
• Blue Hat owns an extensive portfolio of proprietary technologies, patents, artwork copyrights, trademarks and software copyrights

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is a leading producer, developer and operator of augmented reality (AR) games and smart toys in China for children and young adults ages three to 23. The company’s product line includes interactive educational materials, mobile games and toys with mobile game features. Blue Hat’s mobile-connected entertainment platform enables the connection of physical items to mobile devices through wireless technologies, creating a unique interactive user experience.

The global augmented reality (AR) and virtual reality (VR) market is expected to thrive over the foreseeable future, according to Market Research Future analysis published February 12, 2019. The report suggests that the AR/VR market value is likely to reach $767 billion by 2025 as companies begin to adopt the interactive technology across different industry verticals (http://ibn.fm/JJaBV). China’s toy market is soaring as well, with total retail sales of toys and games registering an annual growth rate of nearly 20 percent, reaching RMB276.5 billion in 2017, according to the Hong Kong Trade Development Council (“HKTDC”) (http://ibn.fm/28lAW).

Founded in 2010, Blue Hat utilizes augmented reality technology, motion capture technology, image recognition technology, voice control, light sensing technology, infrared, levitation induction and other trending scientific technologies to create toys and games that children enjoy and that parents want to have in their homes. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction (http://ibn.fm/Y6VVr).

Blue Hat is led by Director and CEO Xiaodong Chen, who has over 20 years of experience in developing and operating toys and related products. The company has developed long-term relationships with preferred distributors, placing its AR interactive entertainment products into internationally known retail chains such as Toys ‘R’ Us (now owned by Tru Kids Inc.) and other retail outlets. Blue Hat also has integrated online and offline sales channels with e-commerce giants and a physical store in Xiamen, China.

For more information, visit the company’s website at www.BlueHatGroup.net

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

• The company’s priority is on research and development of innovative hemp extracts
• ETST aims to be a global supplier of hemp oil enriched with CBD
• Its product sales were up 66 percent for the year ended March 31, 2019, driven by full-spectrum cannabinoids

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, reported in an SEC 10-K filing that it is prioritizing the marketing of CBD-rich hemp oil and consumer education about the oil’s health and nutritional benefits. ETST markets a complete line of high-grade hemp-CBD oils, hemp-CBD caps and CBD pet oils, with the entire line featuring full-spectrum, pure CBD oils obtained through a super-critical CO2 cold-liquid extraction method (http://ibn.fm/SHodY).

This focused marketing strategy has paid off, as ETST reported a 66.4 percent increase in product sales for the year ended March 31, 2019. Sales totaled $770,635, as compared to $463,108 for the same period in 2018. ETST attributed the increase to its line of branded, full-spectrum cannabinoids as the company continues to expand and maintain its core customer base.

ETST’s corporate strategy is “to design and produce CBD-enhanced nutraceutical products for sale to the general public. (It) intend(s) to create high-grade, CBD-rich hemp oil and other CBD-containing products unique to the current market in the nutraceuticals industry. (The company) believe(s) that (its) formulations will set (it) apart from competing products for promoting health.”

The company’s goal is to “offer a wide selection of health and nutrition products through online, clinics, pharmacies and in-store retail,” noting that its “product selection includes many high-quality supplement brands and includes (its) proprietary CBD-rich hemp oil.”

A priority for ETST is also to advance a variety of high-quality hemp extracts with a broad profile of cannabinoids and additional natural molecules found in industrial hemp and to identify their distinct properties. In addition to its marketing efforts, ETST is a biotechnology company that conducts R&D, then formulates, markets and distributes the CBD oil used for its studies to the public.

ETST conducts research through the University of Central Oklahoma and DV Biologics LLC, an independent biologics firm that operates in the fields of hemp-derived cannabinoids, nutraceuticals, pharmaceuticals and medical devices.

Hemp-based CBD is one of at least 80 cannabinoids found in hemp and is non-psychoactive. The company is striving to scale up its processing capability to accommodate new products in its pipeline. These efforts are particularly timely, as Arcview Market Research projects that legal cannabis sales in North America will reach $20.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25 percent from 2016 (http://ibn.fm/oZhJL).

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• VPR Brands LP recently announced the release of its ‘Guide to 2020 U.S. Presidential Candidates on Cannabis Issues’
• The company also released its Q1 2019 financial results, posting increased revenues
• VPR Brands is currently working with other market leaders to promote global cannabis growth, extraction and innovation

VPR Brands LP (OTC: VPRB) recently announced the availability of its ‘Guide to 2020 U.S. Presidential Candidates on Cannabis Issues’. As voters prepare to gather information about the 2020 elections, VPR Brands released the guide, which will act as a single point of reference on every candidate’s stance on cannabis.

“The time has come to elect a president who’ll establish a nationwide standard for cannabis as a legal substance, distributed through a regulated industry with access to capital markets, with pardons and reparations considered for those who found themselves ahead of the law,” VPR Brands CEO Kevin Frija stated in a news release (http://ibn.fm/guhHh).

Of the 27 candidates profiled in the VPR Brands guide (http://ibn.fm/I1O1C), 25 were net-positive on cannabis issues. Only former Health and Human Services Secretary Julian Castro and President Donald Trump scored negatively.

In addition to releasing the guide, VPR Brands also announced its 2019 first-quarter financial results, posting increased revenues and a narrowed net loss as compared to 2018. In addition to increasing its quarterly revenues approximately 31 percent year-over-year to $1.3 million, the company slightly lowered its net loss, from approximately $149,000 in 2018 to approximately $138,000 in 2019. The company continues to maintain strong gross operating margins above 40 percent as well. “[This year] is off to a solid start so far, and we are setting the company’s pace, which will allow us to remain focused on sustainable manageable growth,” Frija added (http://ibn.fm/ptvgv).

“I am very pleased with the increased sales performance we achieved in the first quarter of 2019 as we continue to fine tune our operational efficiencies,” Dan Hoff, COO of VPR Brands LP, stated. He commented on the success of cannabis vapes and CBD products as being integral to the company’s continued growth, as VPR Brands maintains a product portfolio heavily weighted toward these products.

VPR Brands is a publicly traded technology company whose assets include the U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers, as well as e-cigarette products and components. Headquartered in Fort Lauderdale, Florida, the company also develops such vaping products as e-liquids, e-cigarettes and vaporizers for use with cannabis and CBD.

The company’s current portfolio includes:

• GoldLine, which combines premium cannabidiol (CBD) and hemp-based ingredients and extracts coupled with the latest technology;
• HoneyStick, a lifestyle brand that develops cost-effective, upper-tier vaporizers;
• Helium, which brings the vaping experience to a new level with intense flavors;
• Vaporin, which delivers Sub-Ohm series starter kits;
• Vaporx, offering the most current, highest-quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech and Samsung;
• GoldLine Hemp products, which are developed specifically for the convenience store market segment; and
• Vapor Store Direct in Fort Lauderdale, Florida, which is one of the largest vaporizer and e-liquid wholesalers in the United States.

Leveraging its experienced management, VPR Brands is currently working with other market leaders to promote global cannabis growth, extraction and innovation.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• The company has entered an exclusive partnership with PAX Labs
• Supreme recently appointed a new chief information officer and a VP of talent
• The vaping market is projected to reach $47.11 billion by 2025, with North American markets expected to represent the largest share at $20.49 billion

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is out to grow the world’s best cannabis and become a leader in the global industry. As Canada’s only coast-to-coast, premium-cannabis producer, SPRWF sees itself at the center of a global shift toward legalizing cannabis. The company is expanding through strategic partnerships and a strong leadership team. By effectively deploying capital and focusing on disciplined growth and high-quality products, Supreme Cannabis has positioned itself as one of the world’s fastest-growing, premium plant-driven lifestyle companies.

SPRWF is accelerating its growth into the vaporizer market. In June, the company announced an exclusive partnership with PAX Labs (http://ibn.fm/2T4Di). Pending Canada’s federal legalization of vaporizable products, the company will become a foundational brand partner and supplier for PAX Era in Canada. 7ACRES, a wholly owned subsidiary of SPRWF, will be one of only four licensed producers to create cannabis oil pods for the PAX Era, and Supreme Cannabis anticipates selling the branded Era pods coast-to-coast in Canada.

“We have been working hard to ensure Canadian consumers will be able to enjoy quality cannabis concentrates in a convenient pod format,” PAX Canadian General Manager Tim Pellerin stated in a news release (http://ibn.fm/D2wCs). “That is why we are excited to launch our immersive PAX Era experience with quality products from four powerhouse cannabis companies — Aphria, Aurora, Organigram, and Supreme Cannabis.”

PAX operates with the mission of establishing cannabis as a force for good. PAX does not manufacture, produce or sell cannabis, but instead designs and develops premium, app-controlled vaporization technologies and devices. The PAX mobile app allows the user to manage vapor, potency and flavor output. The app also has a security feature that locks the vaporizer from unwanted use. The PAX Era has the added ability to adjust vapor delivery based on the strength of the pull, making sure that no drop is wasted.

PAX has already proven itself as the best-selling pen-and-pod system in the U.S. vaping market and has sold 1.5 million devices worldwide. In 2018, e-cigarettes represented a $3.6 million market in the United States alone (http://ibn.fm/2aYQg). By 2025, the global e-cigarette and vaping market is projected to reach $47.11 billion, with North America expected to have the largest part of that share at $20.49 billion.

The fastest-growing segment of this market is expected to be modular devices that allow users to adjust vapor output to preference (http://ibn.fm/jV49I). In this respect, PAX is ahead of the game, already offering this ability to consumers through its mobile app.

“Together, we expect to deliver 7ACRES’ multi-award-winning flower extracted into oils exclusively for use in North America’s best-selling premium vaporizer, the PAX Era,” added Supreme Cannabis CEO Navdeep Dhaliwal (http://ibn.fm/60qMA). “7ACRES has established itself as the leading Canadian brand for high-end cannabis flower at scale, and as we extend our brand into newly available product categories, we are committed to maintaining the same level of quality our discerning consumer has come to expect. As our brand portfolio grows, we look forward to working with PAX to deliver additional premium brand experiences onto the PAX Era platform.”

In addition, SPRWF continues its next stage of growth with new appointments (http://ibn.fm/jgxnp). Ash Rajendra, an experienced information technology and business leader with a deep understanding of vertically integrated products, has been named the company’s new CIO. As the new VP of talent, Valerie Rother brings more than 16 years of experience in recruitment, talent management and HR business practices to the company. Supreme Cannabis also announced that John Fowler has resigned as director, a role he had held since 2014. Fowler will take on the new position of chief advocacy officer and managing director.

“We are excited to welcome Mr. Rajendra and Ms. Rother to the Supreme Cannabis team,” continued Dhaliwal. “Both bring a wealth of experience and knowledge to drive the company’s next phase of growth. Coupled with our recreational brand, 7ACRES, and the recent addition of our wellness brand, Blissco, and our anticipated acquisition of our global medical brand, Truverra, Supreme Cannabis has evolved as a global leader in premium cannabis brands and products. Our team continues to grow and evolve to meet the demands of this fast-moving industry.”

In additional to 7ACRES, the company’s portfolio includes Cambium Plant Sciences, Medigrow Lesotho, and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF